Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab + Pola-R-CHP vs Pola-R-CHP in Previously Untreated Large B-Cell Lymphoma
NCT06047080Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2023
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of glofitamab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival as determined by Independent Review Facility. Started Sep 2023; status: active, not recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06047080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06047080.